Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -266.60% is 58% below its 5-year average of -169.07%, around the middle of its 5-year range (-603.35%–97.57%).
29.90% below its 12-month average of -205.24%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -18.03%.
EBITDA MARGIN
-266.60%
EBITDA MARGIN AVG TTM
-205.24%
EBITDA MARGIN AVG 3Y
-247.89%
EBITDA MARGIN AVG 5Y
-169.07%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-29.90%
CURRENT VS 3Y AVG
-7.55%
CURRENT VS 5Y AVG
-57.69%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
OmniAb, Inc.
Market Cap
$630.63M
EBITDA Margin
-266.60%
TTM Avg
-205.24%
3Y Avg
-247.89%
5Y Avg
-169.07%
Market Cap
$632.16M
EBITDA Margin
-4381.82%
TTM Avg
-5481.88%
3Y Avg
-5481.88%
5Y Avg
-3660.27%
Market Cap
$634.30M
EBITDA Margin
-0.17%
TTM Avg
-170.79%
3Y Avg
-232.04%
5Y Avg
-156.74%
Market Cap
$619.15M
EBITDA Margin
-79.46%
TTM Avg
-84.20%
3Y Avg
-111.99%
5Y Avg
-123.17%
Market Cap
$656.59M
EBITDA Margin
-178.29%
TTM Avg
-244867.52%
3Y Avg
-123424.79%
5Y Avg
-82415.31%
Market Cap
$657.89M
EBITDA Margin
-5.80%
TTM Avg
-5.80%
3Y Avg
-5.80%
5Y Avg
-5.80%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OmniAb, Inc. (OABI) | $630.63M | -266.60% | -205.24% | -247.89% | -169.07% |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | -4381.82% | -5481.88% | -5481.88% | -3660.27% |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | -0.17% | -170.79% | -232.04% | -156.74% |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | N/A | N/A | N/A | N/A |
| SOPHiA GENETICS S.A. (SOPH)vs › | $619.15M | -79.46% | -84.20% | -111.99% | -123.17% |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | -178.29% | -244867.52% | -123424.79% | -82415.31% |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | -5.80% | -5.80% | -5.80% | -5.80% |
| Annexon, Inc. (ANNX)vs › | $660.29M | N/A | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 40.74% | 33.91% | -21.02% | 1.67% |
Gross Margin
-18.2%
EBITDA Margin
-266.6%
Operating Margin
-383.1%
Net Margin
-115.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -18.03% |
| 2026-03-31 | -13.19% |
| 2025-12-31 | -94.73% |
| 2025-09-30 | -603.35% |
| 2025-06-30 | -296.90% |
| 2025-03-31 | -339.46% |
| 2024-12-31 | -76.58% |
| 2024-09-30 | -355.63% |
| 2024-06-30 | -134.02% |
| 2024-03-31 | -463.14% |
| 2023-12-31 | -337.45% |
| 2023-09-30 | -282.18% |
| 2023-06-30 | -207.96% |
| 2023-03-31 | -23.85% |
| 2022-12-31 | 34.57% |
| 2022-09-30 | -153.62% |
| 2022-06-30 | -109.90% |
| 2022-03-31 | -48.44% |
| 2021-12-31 | -0.58% |
| 2021-09-30 | 97.57% |
| 2021-06-30 | -123.58% |
| 2021-03-31 | -100.42% |
| 2020-12-31 | 8.52% |
| 2020-09-30 | -105.69% |
